24 noviembre 2014
A new study shows «extremely promising” early phase 1 clinical trial results for the investigational drug AG-120 against the subset of patients with acute myeloid leukemia (AML) harboring mutations in the gene IDH.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/gjIs4nzrK1I/141124180049.htm
